['diabetic macular edema']
['ivt aflibercept', 'sham sc', 'sc cls-ta']

        Inclusion Criteria:

          -  Clinical diagnosis of type 1 or type 2 DM

          -  DME with central involvement (> 300 µm in the central subfield on spectral-domain
             optical coherence tomography [SD-OCT], in the study eye

          -  ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye

          -  Naïve to local pharmacologic treatment for DME in the study eye

        Exclusion Criteria:

          -  IOP > 21 mmHg in the study eye at Visit 1 (Day -30 to -1); subjects are not excluded
             if IOP is <22 mmHg in the study eye with no more than 1 IOP lowering medication

          -  Any previous treatment in the study eye with an ocular corticosteroid implant

          -  Has significant media opacity precluding evaluation of retina and vitreous in the
             study eye.

          -  History of glaucoma or optic nerve head change consistent with glaucoma damage

          -  History of glaucoma surgery

          -  History of clinically significant IOP elevation in response to corticosteroid
             treatment ("steroid responder")
      